Premium
The effect of surgery with radiation on pelvic Ewing sarcoma survival
Author(s) -
Ng Vincent Y.,
Jones Robin,
Bompadre Viviana,
Louie Philip,
Punt Stephanie,
Conrad Ernest U.
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24081
Subject(s) - medicine , surgery , retrospective cohort study , sarcoma , radiation therapy , chemotherapy , complication , cohort , stage (stratigraphy) , pathology , paleontology , biology
Background Pelvic Ewing sarcoma (ES) has poorer outcomes than extremity‐based lesions and the method of local control is controversial. Methods A retrospective review was performed of 40 primary pelvic or sacral ES treated by a single surgeon. All received modern chemotherapy and those that received radiation were treated with modern dosages. Results Fifty‐five percent were disease‐free at latest follow‐up (median, 83.1 mos). Sixty‐one percent had ≥99% necrosis, which was associated with 65% disease‐free survival. Larger size ( P = 0.016) and the absence of metastatic disease ( P = 0.005) was predictive of survival. Eighty‐three percent of relapsed patients were DOD. Half of patients who received surgery alone or RT alone have NED while 57% of those who received S/RT have NED. Complication rates were 69% (S/RT), 75% (surgery alone), 10% (RT alone). Functional outcomes were similar. Conclusion Primary pelvic ES is localized at presentation in 50% and the absence of metastases is the strongest predictor for survival. Chemotherapy is key, but excellent histologic response is neither a guarantee nor a necessity for survival. More than one‐third die despite an excellent histologic response and at least one‐third with lung metastases survive. With chemotherapy, radiation, and surgery, reasonable control of disease can be achieved. Level of Evidence III Case‐control or retrospective cohort study. J. Surg. Oncol. 2015;112:861–865 . © 2015 Wiley Periodicals, Inc.